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Abstract
Background: Chronic Kidney Disease (CKD) represents a great burden for the patient and the health system,
particularly if diagnosed at late stages. Consequently, tools to identify patients at high risk of having CKD are
needed, particularly in limited-resources settings where laboratory facilities are scarce. This study aimed to develop
a risk score for prevalent undiagnosed CKD using data from four settings in Peru: a complete risk score including all
associated risk factors and another excluding laboratory-based variables.
Methods: Cross-sectional study. We used two population-based studies: one for developing and internal validation
(CRONICAS), and another (PREVENCION) for external validation. Risk factors included clinical- and laboratory-based
variables, among others: sex, age, hypertension and obesity; and lipid profile, anemia and glucose metabolism. The
outcome was undiagnosed CKD: eGFR < 60 ml/min/1.73m2. We tested the performance of the risk scores using the
area under the receiver operating characteristic (ROC) curve, sensitivity, specificity, positive/negative predictive
values and positive/negative likelihood ratios.
Results: Participants in both studies averaged 57.7 years old, and over 50% were females. Age, hypertension and anemia
were strongly associated with undiagnosed CKD. In the external validation, at a cut-off point of 2, the complete
and laboratory-free risk scores performed similarly well with a ROC area of 76.2% and 76.0%, respectively (P = 0.784).
The best assessment parameter of these risk scores was their negative predictive value: 99.1% and 99.0% for the complete
and laboratory-free, respectively.
Conclusions: The developed risk scores showed a moderate performance as a screening test. People with a score of ≥ 2
points should undergo further testing to rule out CKD. Using the laboratory-free risk score is a practical approach in
developing countries where laboratories are not readily available and undiagnosed CKD has significant morbidity and
mortality.
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Background
Chronic Kidney Disease (CKD) is becoming a health
threat globally. CKD ranks among the top 20 causes of
years of life lost, and in some countries from the Latin
America (LA) and the Caribbean region, it even ranks in
the top 10 [1, 2]. Despite these trends, evidence about
CKD in low- and middle-income countries (LMICs) is
scarce, making it more difficult to assess modifiable risk
factors or to identify potential venues for prevention strat-
egies. Recently, a population-based study in two Peruvian
cities reported a CKD prevalence of 16.8% [3]. Because of
the significant morbidity and mortality of CKD, including
cardiovascular disease and dialysis-dependent kidney fail-
ure, early detection is especially critical in this context.
Thus, given the growing prevalence of CKD, there is a
need to identify high risk subjects to prevent a greater
burden in terms of morbidity and mortality.
Resources are scarce in LMICs like Peru and other
countries in LA challenging the assessment of large pop-
ulations for CKD. A more practical mean of identifying
risk for CKD among individuals is risk scores, because
they take together a set of variables and estimate how
likely it is for a subject to have a given condition. Al-
though many CKD risk scores have been summarized in
a recent review [4], the available evidence suggest some
research gaps, including, for example, that none of these
risk scores have been developed in populations from LA.
Etiologies for CKD are different in LMICs relative to
high-income countries. This could explain why people
from LA have different CKD prevalence rates when
compared to Mexican-Americans, whites and blacks liv-
ing in the USA [5]. Therefore, risk scores for these pop-
ulations may not be accurately applied in subjects with
Hispanic/Latin background. Many of the risk scores in-
cluded laboratory-based variables. This is challenging in
LMICs where scarce resources also affect the availability
of laboratory infrastructure, which are almost unavail-
able at the primary care level or in rural areas. Some en-
vironmental features had not been included, such as
geographic location. Living in high altitude has an im-
pact on health because hypoxemia challenges physio-
logical systems, including the kidney [6, 7]. Because
globally there are millions of people living over 2000 m
(6561 ft) above the sea level [8], results from high-altitude
sites could be informative and useful for these
populations.
Consequently, we aimed to develop a pragmatic risk
score for prevalent undiagnosed CKD, and to assess its
performance, in terms of sensitivity, sensibility, positive
and negative predictive values, as well as positive and
negative likelihood ratio, with and without laboratory-
based variables. We used data of two population-based
studies conducted in four settings in Peru including sub-
jects living at 3825 m (12,549 ft) above the sea level.
Methods
Data source
This is a cross-sectional analysis using data from the
CRONICAS Cohort Study [9] and the PREVENCION
Study [10]. Cross-sectional data from the third follow-up
round of the CRONICAS Cohort Study, conducted in
year 2013-2014, was used to develop the risk score. Data
from another population-based study, the PREVEN-
CION Study (year 2004-2006), was used for external val-
idation of the risk scores.
Study population
The sample of the CRONICAS Cohort Study [9] was
drawn from four settings in Peru: Lima (highly-urbanized
city at sea level), Puno (including a rural and urban setting
at 3825 m above the sea level) and Tumbes (semi-urban
setting at sea level). This is a population-based study in-
cluding subjects selected following a sex- and age-
stratified (35-44, 45-54, 55-64, and ≥ 65 years) procedure.
In each site 1000 subjects were enrolled. The sample
included subjects whom were full-time residents in
the area and capable of giving informed consent. Only
one subject was recruited per household and the ex-
clusion criteria included: being pregnant, having active
pulmonary tuberculosis, and having any disability pre-
venting them from undergoing anthropometric assess-
ments. Further details about the sampling methods
and procedures of the CRONICAS Cohort Study are
available elsewhere [9].
For the development of the CKD score the initial sample
included 2655 subjects, after excluding subjects with miss-
ing values in the prediction variables there were 2420 indi-
viduals. We further excluded subjects who reported
having CKD (N = 14), because our risk score was for un-
diagnosed CKD; we also excluded subjects with missing
values in key variables to calculate the eGFR (creatinine,
age, sex and race), leaving a total of 2407 subjects. Lastly,
we excluded subjects with BMI >40 kg/m2 or BMI
<18.5 kg/m2, because extreme body mass can affect serum
creatinine levels. Overall, 2368 subjects were included to
develop the risk score (Additional file 1: Figure S1).
The PREVENCION Study [10] is a population-based
study conducted in Arequipa, the second largest city in
Peru at 2335 m above the sea level. The sample was
selected following a probabilistic multistage sampling
process, stratifying the sampling frame by socio-economic
status and geographic location. Socio-economic status
stratification was based on indicators of household sanita-
tion and availability of urban services; regarding stratifica-
tion by geographic location, the city was divided in areas
of approximately 50 blocks and each of these further
divided in 4-5 aggregates of approximately 150 households
each. The PREVENCION researchers aimed to include
≥1600 subjects with at least 200 individuals in each age
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group: 20-34, 35-49, 50-64 and 65-80 years. Further details
about the sampling methods and procedures of the
PREVENCION Study have been published elsewhere [10].
In the validation process of the CKD scores there were
initially 2106 individuals, we then excluded subjects who
reported having the diagnosis of CKD (n = 3), and those
with missing values in the prediction variables, resting
2024 individuals. In order to ensure comparability be-
tween the two studies, we excluded subjects aged
<35 years in the PREVENCION Study, so there were
1611 subjects left. We further excluded subjects with
missing values in key variables to calculate the eGFR
and people with BMI < 18.5 kg/m2 or BMI > 40 kg/m2,
leaving a total sample of 1459 subjects.
Variables
For comparison purposes potential risk factors were
defined similarly in both, the CRONICAS and
PREVENCION studies. Table 1 provides detailed defini-
tions used for various risk factors. Potential risk factors in-
cluded clinical- and laboratory-based variables and all were
assessed as potential risk factors in the development
process [4]. Information was collected by trained fieldwor-
kers through face-to-face interviews, and blood pressure
and anthropometric indicators, i.e. weight and height, were
also measured. Blood pressure measurements were con-
ducted according to the recommendations of the 7th Joint
National Committee on the diagnosis and management of
High Blood Pressure in adults (JNC-7) [11]. Serum Cre-
atinine was analysed from blood samples withdrawn from
each participant. The CRONICAS and PREVENCION
studies followed standardized procedures detailed
elsewhere [9, 10].
The main outcome was CKD defined as an eGFR
<60 mL/min/1.73m2 [12], using the MDRD (Modification
of Diet in Renal Disease) formula, also known as CKD
stage III [13]. For sensitivity analysis, the risk scores for
prevalent undiagnosed CKD were also tested with the
GFR estimated with the CKD-EPI (Chronic Kidney
Disease Epidemiology Collaboration) formula specific for
sex and race [14].
Statistical analysis
Overall approach
Analyses were conducted with STATA 13.0 (StataCorp,
College Station, TX, US). First, characteristics of the study
population were summarized using means and standard
deviations (SD) for numeric variables. Categorical variables
were summarized using percentages and counts. We used
the Chi-squared test to compare differences between
groups. We developed two risk scores for prevalent un-
diagnosed CKD: complete and a laboratory-free risk score.
The complete model included all associated risk factors
(clinical- or laboratory-based variables), and a laboratory-
free approach was pursued excluding information from
blood test.
Development of the risk score
The development process was conducted with the
CRONICAS dataset. Potential risk factors were included
in bivariate models using logistic regressions, with the out-
come being CKD; results were expressed as log of Odds
Ratios (OR) and OR with 95% Confidence Intervals (95%
CI). Risk factors with a P-value < 0.20 were included in
the multivariable model. When all risk factors were
Table 1 Variables definition in the CRONICAS Cohort Study and PREVENCION Study
Variable
Age < 50, 50-69, ≥ 70 years.
Sex Men or women.
Self-history of cardiovascular disease Either heart attack, stroke or heart failure: yes or no.
Smokinga Last 12 months, have you smoked? Yes or no.
Hypertension Defined as blood pressure≥ 140/90 mmHg OR previous diagnosis of hypertension and currently under
treatment [11].
Diabetes Defined as fasting glucose ≥ 126 mg/dL OR diabetes diagnosed by a physician and currently under treatment.
Body Mass Index (BMI) Categories: normal weight as [18.5-25[; overweight as [25-30[; and obesity as ≥ 30Kg/m2.
Central obesity Waist circumference ≥ 90 cm if male or ≥80 cm if female.
Parental history of early heart attack Parents with heart attack before age 60: yes or no.
Anemia Haemoglobin < 13 g/dL if male and < 12 g/dL if female [24].
Total Cholesterol Borderline high or high if total cholesterol ≥200 mg/dL versus desirable if total cholesterol <200 md/dL [25].
HDL Cholesterol High if ≥ 50 mg/dL if female or ≥ 40 mg/dL if male versus low otherwise [25].
LDL Cholesterol Above optimal or high if LDL cholesterol ≥ 100 mg/dL versus optimal otherwise [25].
Triglycerides High > 150 mg/dL or low ≤ 150 mg/dL [25].
aSmoking was not defined in the exact same way, due to data availability: in PREVENCION it was defined as current smoker (yes or no)
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included, we used a stepwise backward elimination tech-
nique until only significant risk factors, at a p-value < 0.05,
remained in the model. To evaluate how accurate was the
predicted prevalence of CKD relative to the observed
prevalence, we used the Hosmer-Lemeshow test [15].
Each category of the risk factors included in the final
model is given a value; these should be added up to cal-
culate the risk. These values were obtained by rounding
up the regression coefficients of the multivariable model.
To determine the optimal cut-off point for the risk
scores, we used the Youden’s index [16].
Validation process
To assess the properties of the risk scores –complete
and laboratory-free– we calculated the area under the
receiver operating characteristic (ROC) curve, sensitivity,
specificity, positive/negative predictive values, percent-
age of correctly classified, and positive/negative likeli-
hood ratios.
We internally validated the performance of our risk
scores with bootstrap procedures. We used 1000 random
samples with replacement to calculate the bootstrap ROC
confidence interval choosing the bias-corrected option
[17]. This procedure was conducted with CRONICAS
dataset. On the other hand, the external validation, in
terms of area under ROC, sensitivity, specificity, negative/
positive predictive values as well as negative/positive likeli-
hood ratios, was conducted with PREVENCION dataset.
Finally, we compared the performance of our risk scores
–complete and laboratory-free– with those previously
developed in other populations [4, 18–20]. These compari-
sons were made by contrasting the areas under the curves
at the corresponding cut-off points. A recent systematic re-
view [4] compiled several risk scores for CKD, of these, we
chose those developed with cross-sectional studies and that
assessed CKD in a similar fashion [18–20]. Although we
were deficient of one or two predictors used in such risk
scores, we strongly felt it was necessary to compare our
risk scores to see if they were superior to existing ones.
Sensitivity analysis
The procedures to develop the risk scores were
re-conducted including different parameters: i) the out-
come, CKD, was estimated with the CKD-EPI equation;
and ii) using the MDRD equation to estimate the eGFR,
subjects with an eGFR < 15 (CKD Stage V) were excluded
of the models. Because there are no current recommenda-
tions as to which equation use in Peru, we aimed to test
our risk score using two different equations to verify if our
risk scores could be used regardless of how eGFR was esti-
mated. Then, we excluded subjects with CKD Stage V be-
cause these subjects could have other conditions than
subjects with eGFR between 15 and 60, thus biasing our
results; in addition, these patients would have a condition
severe enough that a risk prediction tool would be
unnecessary.
Other sensitivity analysis we conducted when develop-
ing the risk scores included adjusting the bivariate model
by study site (as a proxy of altitude above the sea level).
We aimed to see if the association was independent of
geographic location, providing the study sites were at
sea level and at high altitude.
Ethics
All participants in the CRONICAS Cohort Study gave
informed consent and the study protocol was ap-
proved the Institutional Review Boards (IRB) at
Universidad Peruana Cayetano Heredia (Lima, Peru)
and Johns Hopkins University (Baltimore, USA) [9].
Participants in the PREVENCION Study gave informed
consent and the study protocol was approved by the Santa
Maria Catholic University Human Research Committee
(Arequipa, Peru) [10].
Results
Characteristics of the participants
Participants in both studies were 57.7 years old in average,
and over 50% were females. There were differences in mean
BMI and lipid profiles: BMI was higher in CRONICAS
while total cholesterol, HDL-cholesterol and triglycerides
were higher in PREVENCION. Further details about each
study population are depicted in Table 2.
Prevalence of undiagnosed CKD
In CRONICAS, according to the MDRD equation, mean
eGFR was 96.3 (SD: 21.6) and there was a CKD Stage III
or greater prevalence of 3.4% (95% CI: 2.7%-4.2%). In PRE-
VENCION, mean eGFR was 89.6 (SD: 20.1) and there was
a CKD Stage III or greater prevalence of 5.4% (95% CI:
4.3%-6.6%). Mean eGFR (P < 0.001) and the CKD preva-
lence was different between studies (P = 0.003).
CRONICAS-CKD risk score: Development
Table 3 shows risk factors associated with undiagnosed
CKD, both in the univariable and multivariable models.
Risk factors strongly associated with prevalent undiag-
nosed CKD in the multivariable model were age, hyper-
tension and anemia. Age showed the strongest OR: older
age was associated with higher odds of having impaired
eGFR. Likewise, having hypertension and anemia was as-
sociated with almost 5-fold and 4-fold higher odds of
having CKD, respectively.
Regarding the scoring system, for age there were three
categories: <50 years (0 points), 50-69 (1 point) and ≥
70 years (2 points); with regards to hypertension, there
were two categories: no (0 points) and yes (1 point); and
anemia also had two categories: no (0 points) and yes (1
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point). Therefore, the complete risk score could add up to
4 points, whereas the laboratory-free (without anemia)
risk score could add up to 3 points. For both, the
complete and laboratory-free risk scores, the optimal cut-
off point was 2 points (Fig. 1).
Table 4 depicts the performance of the complete and
laboratory-free risk scores; in addition, Fig. 2 shows the
area under the ROC curve for the complete and
laboratory-free risk score: 0.842 and 0.824 (P = 0.03),
respectively. At a cut-off point of 2, the areas under
the curve were not different between the complete
and laboratory-free risk scores: 76.2% versus 76.0%
(P = 0.78).
CRONICAS-CKD risk score: External validation
Using PREVENCION dataset, the complete risk score
with an optimal cut-off point of 2 showed a sensitivity of
70.5%, a specificity of 69.1%, a positive predictive value
of 11.4%, a negative predictive value of 97.6%, a positive
likelihood ratio of 2.3 and a negative likelihood ratio
of 0.4; this yielded a ROC area of 70.0%. The
laboratory-free risk score, at a cut-off point of 2,
showed a sensitivity of 70.5%, a specificity of 69.7%, a
positive predictive value of 11.6%, a negative predict-
ive value of 97.7%, a positive likelihood of 2.3 and a
negative likelihood of 0.4; this yielded a ROC are of
70%. Of note is the high negative predictive value of
the complete and laboratory-free risk scores.
Comparison with other risk scores
At the corresponding threshold points, when ours risk
scores were compared with others, these were very simi-
lar in terms of c-statistics. In addition, the ROC area was
not different between our risk scores and the others, ex-
cept when comparing our complete risk score with that
one from Thailand: 76.2% (ours) versus 72.2% (P = 0.03).
Further details about these comparisons are presented in
Additional file 2: Table S1.
Sensitivity analysis
Additional file 3: Table S2 shows the univariable and
multivariable models when the outcome was defined
using the CKD-EPI equation. If a risk score for undiag-
nosed CKD were to be constructed with eGFR defined
with the CKD-EPI equation, such risk score should also
include personal history of any cardiovascular disease in
addition to age, hypertension and anemia.
Additional file 4: Table S3 shows the univariable
and multivariable models when subjects with eGFR
(according to the MDRD equation) less than 15 were
excluded. If the risk score were to be developed for
subjects with eGFR >15 only, it should also include
triglycerides besides age, hypertension and anemia.
When the bivariate associations were further
adjusted by study site (as a proxy for altitude above
the sea level), the results did not change, signalling that
the associations seemed to be independent of geographic
location.
Table 2 Sociodemographic and clinical characteristics of the
participants
CRONICAS PREVENCION P-value
(n = 2368) (n = 1459)
Sex
Women (%) 50.6 52.3 0.31
Agea
Mean (SD) 57.7 (12.4) 57.1 (12.6) 0.20
Smoke
Yes (%) 12.1 16.2 <0.01
Diabetes
Yes (%) 8.4 6.7 0.06
Fasting Glucose
Mean (SD) 104.1 (42.3) 84.8 (27.8) <0.01
Hypertensiona
Yes (%) 24.0 22.8 0.39
Systolic Blood Pressure
Mean (SD) 118.6 (19.7) 123.3 (20.2) <0.01
Diastolic Blood Pressure
Mean (SD) 72.6 (10.8) 79.2 (9.1) <0.01
Personal History of CVD
Yes (%) 0.9 2.6 <0.01
Anemiaa
Yes (%) 8.1 2.7 <0.01
Haemoglobin
Mean (SD) 14.5 (2.1) 15.1 (1.7) <0.01
BMI
Mean (SD) 27.9 (4.1) 27.2 (4.0) <0.01
Waist Circumference
Mean (SD) 93.0 (10.1) 92.8 (10.9) 0.51
Total Cholesterol
Mean (SD) 197.8 (40.5) 206.7 (39.2) <0.01
HDL-Cholesterol
Mean (SD) 45.7 (12.7) 47.9 (10.1) <0.01
LDL-Cholesterol
Mean (SD) 120.7 (34.4) 122.6 (31.5) 0.09
Triglycerides
Mean (SD) 158.6 (92.9) 184.0 (91.3) <0.01
All these risk factors were assessed in the bivariate model
aIndicates risk factors included in the final adjusted model
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Table 3 Associated factors with undiagnosed CKD: Beta Coefficients and Odds Ratios using CRONICAS database (N = 2368)
Univariable Model Multivariable Model Risk Score
(points)Coefficient (SE) OR (95%CI, P-value) Coefficient (SE) OR (95%CI, P-value)
Sex
Women 1 1
Men 0.18 (0.23) 1.20 (0.76-1.87, 0.45)
Age
< 50 1 1 1 1 0
50-69 1.82 (0.61) 6.17 (1.87-20.32, < 0.01) 1.54 (0.61) 4.66 (1.40-15.53, 0.01) 1
≥ 70 3.48 (0.60) 32.30 (10.00-104.40, < 0.01) 2.59 (0.61) 13.38 (4.01-44.62, < 0.01) 2
Personal History of any CVD
No 1 1
Yes 1.59 (0.63) 4.91 (1.42-17.09, 0.01)
Personal History of Infarction
No 1 1
Yes −0.72 (1.04) 0.49 (0.06-3.75, 0.49)
Personal History of Stroke
No 1 1
Yes −3.38 (1.01) 0.03 (0.01-0.25, < 0.01)
Personal History of Heart Failure
No 1 1
Yes −2.67 (1.23) 0.07 (0.01-0.77, 0.03)
Smoking
No 1 1
Yes −0.74 (0.47) 0.48 (0.19-1.19, 0.11)
Hypertension
No 1 1 1 1 0
Yes 2.15 (0.25) 8.60 (5.25-14.09, < 0.01) 1.54 (0.27) 4.65 (2.76-7.83, < 0.01) 1
Diabetes
No 1 1
Yes 0.80 (0.29) 2.22 (1.26-3.90, < 0.01)
BMI
Normal 1 1
Overweight −0.22 (0.27) 0.80 (0.47-1.37, 0.42)
Obesity −0.20 (0.30) 0.82 (0.45-1.48, 0.50)
Central Obesity
No 1 1
Yes 0.29 (0.30) 1.34 (0.75-2.40, 0.33)
Parents w/Infraction <60y
No 1 1
Yes −0.74 (0.72) 0.48 (0.12-1.96. 0.30)
Anemia
No 1 1 1 1 0
Yes 1.82 (0.25) 6.16 (3.76-10.09, < 0.01) 1.27 (0.28) 3.56 (2.07-6. 21, < 0.01) 1
Carrillo-Larco et al. BMC Nephrology  (2017) 18:343 Page 6 of 11
Table 3 Associated factors with undiagnosed CKD: Beta Coefficients and Odds Ratios using CRONICAS database (N = 2368)
(Continued)
Univariable Model Multivariable Model Risk Score
(points)Coefficient (SE) OR (95%CI, P-value) Coefficient (SE) OR (95%CI, P-value)
Total Cholesterol
Desirable 1
Borderline High/High 0.31 (0.23) 1.36 (0.87-2.13, 0.18)
HDL-Cholesterol
Low 1 1
High −0.08 (0.23) 0.92 (0.59-1.44, 0.71)
LDL-Cholesterol
Optimal 1 1
Above Optimal/High −0.16 (0.25) 0.85 (0.53-1.38, 0.52)
Triglycerides
≤ 150 1 1
> 150 0.28 (0.23) 1.32 (0.85-2.07, 0.22)
The multivariable model was created following a backward elimination approach: all variables with p < 0.20 in the univariable model were fitted and one by one
removed starting with the least significant until the final model only included significant variables (p < 0.05). Although personal history of stroke or personal
history of heart failure could have been included in the multivariable model, these were not included because their estimates were very small and personal
history of any CVD, which included the aforementioned conditions, had a higher and significant estimate. For the final multivariable model: Hosmer-Lemeshow X2
test: 4.13 with a p-value of 0.53. Area under de ROC curve of the final model was 0.8445. Each category of the risk factors included in the final model is given the
corresponding point (see last column), and add up. For both, the complete and laboratory-free risk scores, the optimal cut-off point was 2 points: if a subject
reaches 2+ points he/she would have greater odds of having CKD at that time; for example a 75-year old men with hypertension but without anemia would score
3 (2 points of age and 1 for hypertension)
Fig. 1 Algorithm to use the CRONICAS-CKD risk score in the general population
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Discussion
Main results
In Peru, an algorithm to identify subjects aged 35+ years
in the general population with prevalent undiagnosed
CKD, defined as an eGFR <60 ml/min/1.73m2 according
to the MDRD equation, should include age of the pa-
tient, as well as hypertension and anemia status. Further-
more, if no laboratory facilities are available, just
including age and hypertension status is a sensitive and
specific approach too. The risk score herein presented
should be used with the GFR estimated using the MDRD
equation and including subjects with eGFR in any range.
The risk scores are relevant in the primary care level or
in rural settings where subjects with a negative result in
the risk score may not need further testing; nonetheless,
a positive result would require further exploration. How-
ever, because these findings depend on the condition’s
prevalence, they should be interpreted with caution in
each setting. Since previous risk scores have not been
developed exclusively with populations from Latin
America or the Andes region, we offer a practical tool to
discard prevalent undiagnosed CKD in these
populations.
Interpretation of results
The positive and negative predictive values depend on the
prevalence of the condition; the low CKD prevalence in
the study population could explain the low positive pre-
dictive value. Furthermore, we reported high negative pre-
dictive values, meaning that, of all tested subjects who had
a negative result, over 99% do not have CKD. This is a
good feature because subsequent tests could be expensive,
and our risk scores show that subjects with negative re-
sults are likely not to have CKD, and thus may not need
to undergo further testing. However, negative and positive
predictive values depend on the prevalence of the
Table 4 Performance of the CRONICAS-CKD risk score for undiagnosed CKD using CRONICAS dataset
Total score Youden Index Sensitivity Specificity PPV NPV Correctly classified LR+ LR-
Complete Risk Score
≥ 0 0% 100.0% 0.0% 3.4% – 3.4% 1.00 –
≥ 1 27.7% 100.0% 27. 7% 4.6% 100.0% 30.1% 1.4 0.00
≥ 2 52.5% 82.5% 70.0% 8.8% 99.1% 70.4% 2.8 0.3
≥ 3 50.7% 60.0% 90.7% 18.3% 98.5% 89.6% 6.4 0.4
≥ 4 16.1% 17.5% 98.6% 29.8% 97.2% 95.8% 12.1 0.8
laboratory-free Risk Score
≥ 0 0% 100.0% 00.0% 3.4% – 3.4% 1.0 –
≥ 1 28.3% 98.8% 29.6% 4.7% 99.9% 31.9% 1.4 0.0
≥ 2 52.0% 80.0% 72.0% 9.1% 99.0% 72.3% 2.9 0.3
≥ 3 41.3% 48.8% 92.6% 18.7% 98.1% 91.1% 6.6 0.6
PPV Positive predictive value, NPV Negative predictive value, LR+ Positive likelihood ratio, LR- Negative likelihood ratio
PPV and NPV were calculated with a CKD prevalence of 3.38%. At a cut-off point of 2, the areas under the ROC were similar between the complete and
laboratory-free risk scores (76.24% versus 75.99%, P = 0.784). The italicized figures highlight the characteristics at the proposed cut-off point
Fig. 2 Receive operating characteristic (ROC) curve of the
CRONICAS-CKD risk score for undiagnosed CKD using CRONICAS
database. (a) complete risk score, the 95% CI of the area under the
ROC curve is 79.6%-88.0%; (b) laboratory-free risk score, the 95% CI
of the area under the ROC curve is 77.7%-86.8%. The areas between
these curves were different (P = 0.028)
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condition. Thus, interpretation of these figures should be
made with caution and according to local epidemiology.
Moreover, since the area under the ROC curves were not
different between the complete and laboratory-free scores
at a threshold of 2 points, this suggests that the risk scores
could be interchangeably, prioritizing the laboratory-free
risk score because it is a much easier approach. Overall,
given the negative predictive value is higher than the posi-
tive predictive value, we suggest using the risk scores as a
screening tool discard CKD; however, a positive result
would need further confirmation.
When comparing ours risk score with others similarly
developed, the results showed there were not strong differ-
ences. This suggests ours risk scores perform as well as
those previously developed [18–20]. Nonetheless, ours
have fewer variables, particularly the laboratory-free risk
score. This accounts for its simplicity and easy use, which
are valuable features in resource-limited settings where
clinically-assessed variables may be the only available tools.
Comparison of results
The fact that our risk scores perform similarly to those
previously developed (Additional file 2: Table S1) could
be because the risk scores included a similar base: age,
hypertension and anemia status. This highlights the rele-
vance of these variables to identify CKD. However, the
higher or lower ROC area could be because other risk
scores included more predictors such as proteinuria, self-
history of kidney stones, and peripheral vascular diseases,
among others; some of these variables are laboratory-
based, restraining their availability in resource-limited or
rural areas. Although we did not assess these parameters,
our risk scores still presented a moderate performance.
Limitations and opportunities of using previous CKD risk
scores
Although some of the previous risk scores claimed to have
been developed in multi-ethnic populations [4], none was
developed mainly including subjects from Latin America
or the Andes region. Even though subjects with Hispanic
or Latino background in the USA have lower rates of
eGFR < 60 relative to Mexican Americans, whites and
black individuals, when stratified by sex, males have simi-
lar rates across these ethnicities and when stratified by
age, Hispanic/Latinos aged 45-54 years have higher rates
[21]. Thus probably, Hispanic and Latinos need to be
screened differently than native Americans. Because inter-
national and internal migration keeps growing, it becomes
relevant to have specific tools to accurately identify sub-
jects at increased CKD risk. These specific tools could be
used at medical appointments based on the patient’s eth-
nic background; for example, patients from the Latin
America or Andes region could be assessed with our risk
scores, probably providing more accurate results than if
they had been assessed with other scores. Notwithstanding,
this warrants further verification.
Relevance and implications
The risk scores herein presented, included age, that
could be assessed by anyone with a questionnaire; blood
pressure, that could be assessed by any one with little
training and minimal supervision; and anemia status, for
which blood samples can be taken by anyone with min-
imal training and there are also point-of-care options.
Thus, our risk scores could be self-administered or ap-
plied by community-health workers. Community-health
workers seem to be a cost-effective approach in LMICs,
although this approach has been mostly assessed in the
field of communicable diseases, maternal and new born
health [22]. Our results, along with others in the litera-
ture, could be used to assess how community-health
workers identify and adequately refer subjects with un-
diagnosed CKD. According to our risk score, 50+ year
old subjects with hypertension should be looked up for
CKD; therefore, health personnel or community-health
workers could identify and refer these subjects.
The Peruvian Society of Nephrology suggests that at
the primary care level a general physician should identify
subjects with risk factors for CKD. In addition, they sug-
gest to take a complete urine test looking for proteinuria
and also to assess micro-albuminuria [23]. Unfortu-
nately, these tests may not be available everywhere, or
may not be affordable. Furthermore, and although urine
dipsticks could also be an option, securing their
provision across the country would face major setbacks
too, limiting their application. Thus, our risk score could
provide an additional filter to classify subjects who
should undergo further examinations. Nevertheless, our
risk score should be further studied before strong use
recommendations are made.
Strengths and limitations
We used two different datasets for internal and external
validation. Furthermore, the data we used included sub-
jects of four different Peruvian cities, encompassing
rural and urban settings, as well as different geographic
profiles. Although the data was not nationally represen-
tative, the broad range of participants could make our
results informative and applicable to other Peruvian set-
tings, and to other settings with similar characteristics in
the Latin American or Andes region.
Nevertheless, limitations must be highlighted. First, we
did not include other potential risk factors assessed by
previous risk scores, including albumin excretion or pro-
teinuria. Second, our CKD definition was only based on
eGFR, although other parameters could have been in-
cluded (e.g., albuminuria or structural abnormalities in
the kidney) [5]. This limitation is shared with other risk
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scores [4]. Although a previous study in Peru reported
that proteinuria was the most common criterion for
CKD [3], its assessment is not available everywhere, thus
not fulfilling our main goal: to develop an easy-to-apply
risk score for prevalent undiagnosed CKD, which could
be used in any medical facility regardless of the availabil-
ity of laboratory facilities. Furthermore, because albu-
minuria is an important predictor of decline in eGFR,
subjects at high risk in our scores could undergo such
test, and not before, saving resources. Third, including
elderly people (e.g. subjects aged ≥70 years) could have
seen as a limitation, because many would have low eGFR
and multi-morbidity accounting for the low specificity of
the risk scores. Fourth, we could not define the etiology
of anemia. This could account for the low specificity of
the complete risk score, because a 50-year-old person
with anemia due to blood loss would be classified as at
higher risk of CKD. Finally, we did not have access to
the participants’ medical records, which could have been
useful to identify more CKD patients who, due to any
reasons, may have been unaware of their condition when
they were invited to participate in the studies. However,
because health care is mostly curative-oriented, we be-
lieve a patient who underwent creatinine evaluation (or
any other test to assess kidney function) without being
informed of his/her condition, would be extremely rare.
This scenario also assumes that laboratory facilities are
widely available, which is not true; on this fact relies the
importance of our risk scores, because it would allow
identifying high-risk subjects who should be then re-
ferred to a laboratory facility.
Conclusions
Including hypertension and age in a risk score is a useful
first approach to screen for prevalent undiagnosed CKD;
adding anemia status to these variables did not improve
much the performance of the risk score meaning that it
is not compulsory to have laboratory facilities to apply
the risk score. In LMIC, where laboratory facilities are
still scarce, pragmatic approaches, as the ones herein de-
scribed, could be a useful screening tool to identify cases
of CKD and thus prevent its great health burden in
terms of morbidity and mortality.
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